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Abstract: Cold atmospheric plasma (CAP) treatment is a rapidly expanding and emerging technology
for cancer treatment. Direct CAP jet irradiation is limited to the skin and it can also be invoked
as a supplement therapy during surgery as it only causes cell death in the upper three to five cell
layers. However, the current cannulas from which the plasma emanates are too large for intracranial
applications. To enhance efficiency and expand the applicability of the CAP method for brain tumors
and reduce the gas flow rate and size of the plasma jet, a novel micro-sized CAP device (µCAP)
was developed and employed to target glioblastoma tumors in the murine brain. Various plasma
diagnostic techniques were applied to evaluate the physics of helium µCAP such as electron density,
discharge voltage, and optical emission spectroscopy (OES). The direct and indirect effects of µCAP
on glioblastoma (U87MG-RedFluc) cancer cells were investigated in vitro. The results indicate that
µCAP generates short- and long-lived species and radicals (i.e., hydroxyl radical (•OH), hydrogen
peroxide (H2O2), and nitrite (NO2−), etc.) with increasing tumor cell death in a dose-dependent
manner. Translation of these findings to an in vivo setting demonstrates that intracranial µCAP is
effective at preventing glioblastoma tumor growth in the mouse brain. The µCAP device can be
safely used in mice, resulting in suppression of tumor growth. These initial observations establish the
µCAP device as a potentially useful ablative therapy tool in the treatment of glioblastoma.
Keywords: micro-sized plasma device; glioblastoma; reactive oxygen species; reactive nitrogen
species; cancer therapy
1. Introduction
Plasma is an ionized gas consisting of positive/negative charges, radicals, neural atoms and
ultraviolet (UV) photons, that is, a gaseous matter with quasi-neutral charges [1–3]. Atmospheric
plasma at or near ambient temperature has led to a new field of plasma medicine [4,5], and cold
atmospheric plasma (CAP) has attracted a lot of attentions due to its remarkable potential to affect
biological processes [2,6]. In this context, the potential of CAP in diverse bio-medical applications has
been explored, including disinfection, wound treatments, control of inflammation, blood coagulation,
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cancer therapy, and regenerative medicine [7–11]. The efficacy of CAP in the proposed applications
relies on the synergistic action of the reactive oxygen species (ROS), reactive nitrogen species (RNS),
free radicals, UV photons, charged particles, and electric fields [12–15]. A low dose of ROS and RNS
was reported to induce cell proliferation as well as cell death, while a high dose of ROS/RNS can
damage proteins, lipids, DNA, and induce apoptosis [16–19]. Some results also indicated that exposing
cancer cells to CAP resulted in the production of free radicals that could cause apoptotic cell death [20].
Many studies of CAP for cancer therapy have indicated that CAP does not harm normal tissue when
applied at the appropriate dosages [21–24]. Taken together, CAP therapy has been introduced as a cost
effective, rapid and selective treatment modality for killing cancer cells.
CAP may be generated by a range of different plasma devices such as the plasma jet, dielectric
barrier discharge, corona discharge, and gliding arc [25–28]. CAP-generated plasma can be directly
applied to skin cancers. However, most cancers occur inside the body, therefore plasma irradiation is
not practical due to the high voltage, the formation of discharge in the organ, gas delivery and plasma
probe volume [29]. The biological effects of micro-sized plasma were studied in vitro and in vivo
earlier [29–31]. However, these studies were not completely successful in carrying out CAP treatment
at a specific position inside the body of animals. In this regard, glioblastoma is a highly malignant
aggressive neoplasm of the primary central nervous system characterized by rapid growth, extensive
angiogenesis, and resistance to all current therapies [32,33]. The major limitations of glioblastoma
tumor treatment and eventual tumor recurrence are: (1) that the brain is susceptible to damage with
conventional therapies; (2) tumor cells are very resistant to conventional therapies; (3) many drugs
cannot cross the blood–brain barrier to act on brain tumors; and (4) the brain has a very limited capacity
to repair itself [32,34]. Thus, it is necessary to develop a plasma device with a reduced gas flow rate
and size, which can potentially be used in vivo by circumventing the problems listed above. Here,
a new micro-sized CAP (µCAP) device employing helium gas was developed, and the effect of µCAP
on glioblastoma both in vitro and in vivo was evaluated.
2. Results
2.1. µCAP and Optical Spectrum
Figure 1a illustrates the µCAP setup used in this work. Figure 1b illustrates µCAP direct treatment
in which the µCAP was used to treat culture medium containing glioblastoma cancer cells. Figure 1c
shows µCAP indirect treatment in which the µCAP was used to first treat deionized (DI) water. After
treatment, the DI water was transferred to culture medium containing cells (70 µL Dulbecco’s Modified
Eagle Medium (containing cells) + 30 µL treated DI water, total 100 µL). The times for both direct and
indirect treatment were 5, 10, 30, 60, and 120 s. Figure 1d shows the spectrum of the He µCAP with
a flow rate of 0.1 L/min. The identification of the emission line and bands was performed mainly
according to [35]. The peaks of 315 nm, 337 nm, 357 nm, and 380 nm represent the photon emission
intensity as the results of excited N2 drops from the state C3Πu to B3Πg with different upper and
lower vibration quantum numbers. The 281-nm peak represents the photon emitted by excited NO
drops from A2Σ+ to X2Π [35]. The helium bands were assigned between 500 and 750 nm as shown in
Figure 1d. Species at a wavelength of 309 nm could be defined as OH. Both He bands between 250 nm
and 425 nm could be defined as ROS/RNS. The nitrogen and OH emission bands likely arise from the
helium supply and ambient air.
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Figure 1. (a) Schematic representation of the micro-sized cold atmospheric plasma setup; (b) µCAP 
direct treatment: µCAP was directly applied to cells in DMEM (100 µL); (c) µCAP indirect treatment: 
DI water was treated with µCAP and then applied to cells in DMEM (70 µL DMEM + 30 µL treated 
DI water); (d) Optical emission spectrum detected from the He µCAP using UV-visible-NIR, in the 
250–850 nm wavelength range. ROS: reactive oxygen species; RNS: reactive nitrogen species; CAP: 
cold atmospheric plasma; µCAP: micro-sized CAP; DMEM: Dulbecco’s Modified Eagle Medium; DI: 
Deionized; µCAP: Micro-sized cold atmospheric plasma; AC: Alternating current 
2.2. Electron Density of He µCAP Jet 
The experimental Rayleigh microwave scattering (RMS) system is shown in Figure 2a. The 
dependence of the output RMS signal on parameters of the scattering channel can be expressed as 
𝑈 = 𝐴𝜎𝑉 , where 𝐴  is the proportionality coefficient ( 𝐴 = 263.8 𝑉𝛺/𝑐𝑚2 ) and 𝑉  is the plasma 
volume. The volume of the plasma column was determined from intensified charged-coupled device 
(ICCD) images. 𝜎  is plasma conductivity using the following expression: 𝜎 = 2.82 × 10−4𝑛𝑒𝑣𝑚/
(2 + 𝑣𝑚
2 ), 𝛺−1𝑐𝑚−1, where 𝑣𝑚 is the frequency of the electron-neutral collisions, 𝑛𝑒 is the plasma 
density, and 𝜔  is the angular frequency [36,37]. Combining these equations yields 𝑛𝑒 =
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in Figure 2b, and the total electron number for one discharge period is 2.4 × 109. 
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Figure 1. (a) Schematic representation of the micro-sized cold atmospheric plasma setup; (b) µCAP
direct treatment: µCAP was directly applied to cells in DMEM (100 µL); (c) µCAP indirect treatment:
DI water was treated with µCAP and then applied to cells in DMEM (70 µL DMEM + 30 µL treated
DI water); (d) Optical emission spectrum detected from the He µCAP using UV-visible-NIR, in the
250–850 nm wavelength range. ROS: reactive oxygen species; RNS: reactive nitrogen species; CAP:
cold atmospheric plasma; µCAP: micro-sized CAP; D E : Dulbecco’s odified Eagle edium; DI:
Deionized; µCAP: icro-sized cold atmospheric plasma; AC: Alternating current.
2.2. Electron Density of He µCAP Jet
The experimental Rayleigh microwave scattering (RMS) system is shown in Figure 2a.
The dependence of the output RMS signal on parameters of the scattering channel can be expressed as
U = AσV, where A is the proportionality coefficient (A = 263.8 VΩ/cm2) and V is the plasma
volume. The volume of the plasma column was determined from intensified charged-coupled
device (ICCD) images. σ is plasma conductivity using the following expression: σ = 2.82 ×
10−4nevm/
(
ω2 + v2m
)
, Ω−1cm−1, where vm is the frequency of the electron-neutral collisions, ne
is the plasma density, and ω is the angular frequency [36,37]. Combining these equations yields
ne =
((
ω2 + v2m
)
U
)
/
((
2.82× 10−4 Avm
)
V
)
. Therefore, we can calculate the total electron number
in the plasma as Ne = neV = U
(
ω2 + v2m
)
/
(
2.82× 10−4 Avm
)
. The electron number of He µCAP is
presented in Figure 2b, and the total electron number for one discharge period is 2.4× 109.
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Figure 2. Schematics of the Rayleigh microwave scattering (RMS) experimental setup (a), as well as the
electron number and discharge voltage of He (b). He: Helium.
2.3. Detection of RNS Generated by µCAP
µCAP treatment of DI water and Dulbecco’s Modified Eagle Medium (DMEM) were performed
to induce changes in the concentration of ROS and RNS as a function of the treatment time. Indeed,
as shown in Figure 3, the NO2− concentration in He µCAP-treated DI water and DMEM increases
with treatment duration. The NO2− mainly originates as NO (N2 + e→ 2N + e, N + O2 → NO + O,
4NO + O2 + 2H2O→ 4NO2− + 4H+) [38–40], while most of NO is formed in the gas phase during the
afterglow a few milliseconds after the discharge pulse. The NO2− concentration in DMEM treated
with He µCAP is higher than that in DI water (p < 0.05 for all treatment times). On the other hand,
DMEM comprises over 30 components such inorganic salts, amino acids and vitamins, while the effect
of plasma irradiation on these compounds is still unknown. Plasma might react with amino acids to
form NO2−, which provides a possible explanation for higher NO2− concentration in DMEM than in
DI water. Plasma-activated media produces a lot of species, including NO3−. In our previous study,
the Ph range of plasma solutions was around 5.0 to 6.0 [16]. On the other hand, different concentrations
of H2O2 show a Ph range from 4.5 to 6.2. Therefore, Ph of Mcap should be between 4.5 and 6.0.
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Figure 3. RNS concentration in He µCAP-treated DI water (a) and DMEM (b). Student t-test was
performed, and the statistical significance compared to µCAP 5 s treatment is indicated as * p < 0.05,
** p < 0.01, *** p < 0.001. (n = 3).
2.4. Assess Relative Concentration of Hydroxyl Radical
Methylene blue (MB) was used to assess the relative concentration of hydroxyl radicals (•OH). It is
known that MB reacts with •OH aqueous solutions, leading to a visible color change [41]. As shown
in Figure 4, the relative MB concentration decreases with treatment time of He µCAP. The relative
MB concentration decreases by 9.3% after He µCAP-treated DI water for 120 s. While this change is
significant, He µCAP-treated DMEM showed a stronger degradation action (14.7%), suggesting that
more short-living reactive species are generated in DMEM. Plasma reacting with DMEM might form
a new product that reacts with methylene blue, which may explain why He Mcap-treated DMEM
showed a stronger degradation action than DI water. Overall, these findings demonstrate that there is
an increase in the relative concentration of •OH as a function of µCAP treatment time.
2.5. Detection of ROS Generated by µCAP
Figure 5 shows the ROS concentration dependence on treatment time in He µCAP-treated DI
water and DMEM. H2O2 generation might be attributed to the high electron density and energy of
the plasma (He → He+ + e, He+ + H2O → H2O+ + He, H2O+ + H2O → H3O+ + •OH; He + e →
He * + e, He * + H2O→ He + •OH + H·; H2O + e→ H2O * + e, H2O *→ •OH + H·; •OH + •OH
→ H2O2) [42,43]. The H2O2 concentration increases with treatment duration for both DI water and
DMEM, although the concentration of H2O2 generated in DI water is higher than DMEM.
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Figure 4. Relative methylene blue (MB) concentration for assessing the concentration of hydroxyl
free radicals in He µCAP-treated DI water (a) and MEM (b). Student t-test was performed, and
the statistical significance compared to MB without µCAP treatment (0 s) is indicated as * p < 0.05,
** p < 0.01, *** p < 0.001. (n = 3).
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Figure 5. H2O2 concentration in µCAP-treated DI water (a) and D E (b). Student t-test was
perfor ed, and the statistical significance compared to µCAP 5 second treatment is indicated as
* p < 0.05, ** p < 0.01, *** p < 0.001. (n = 3).
2.6. Cell Viability Follow In Vitro µCAP Treatment Duration
Figure 6a shows the cell viability of the glioblastoma cancer cells treated with He µCAP indirect
treatment after 24 and 48 h. The cell viability after 24 h incubation (normalized by DMEM control)
decreased by approximately 14.2%, 19.9%, 25.4%, 29.0%, 34.7%, and 39.2%, according to 0, 5, 10, 30, 60,
Cancers 2017, 9, 61 7 of 16
and 120 s treatment durations, respectively. After 48 h of incubation, the cell viability decreased by
approximately 18.3%, 35.6%, 34.8%, 41.1%, 54.7%, and 51.4%, for 0, 5, 10, 30, 60, and 120 s treatment
durations, respectively. Figure 6b shows the cell viability of glioblastoma cancer cells after 24 and 48 h
incubation with He µCAP direct treatment (treat 100 µL media containing cells) for 0, 5, 10, 30, 60, and
120 s duration. The cell viability of the glioblastoma cancer cells after 24-h incubation (normalized
by control) decreased by approximately 15.4%, 27.1%, 28.9%, 44.1%, and 65.1%, according to 5, 10, 30,
60, and 120 s treatment durations, respectively. Similar dose-dependent (i.e., increase treatment time)
decreases in cell viability were found with 48-h incubation.
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summary data (n = 3/group) indicates that the tumor volume in control aggressively increased 
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Figure 7. In vivo targeting of glioblastoma tumor with He µCAP. (a) Photograph of a new µCAP device
for plasma delivery through an intracranial endoscopic tube to target glioblastoma tumors in the mouse
brain; (b) Representative in vivo bioluminescence images illustrating glioblastoma tumor volume (i.e.,
light emission or radiance) at baseline and 2 days following He µCAP or vehicle (helium) treatment.
Areas of high photon emission are shown in red and low are shown in blue; (c) Group summary data
(n = 3/group) indicates that the tumor volume in control aggressively increased following treatment,
whereas He µCAP delivery maintained tumor volume below basal levels.
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3. Discussion
CAP has received considerable attention for its potential biomedical applications. Emerging
fields of application of CAP include wound healing, sterilization of infected tissue, inactivation of
microorganisms, tooth bleaching, blood coagulation, skin regeneration, and cancer therapy. This has
been collectively termed ‘plasma medicine’. Both direct and indirect applications of CAP have been
shown to be effective for treating various cancer cells in vitro and in vivo [11]. However, as discussed
above, the treatment of tumors deep within the body has been hampered by the limitations of CAP
delivery tools. Thus, we aimed to develop and study how application of a novel He µCAP device
could induce high cell death both in vitro and in vivo.
Treating culture media containing cells (direct treatment) was compared to treating DI water and
removing it to culture media containing cells (indirect treatment). Our findings suggest that both He
µCAP direct/indirect treatment could induce high cell death in glioblastoma cancer cells (Figure 6),
although in general direct treatment was more effective than indirect treatment. Plasma contains the
energy ions, free radicals, reactive species, UV radiation, and the transient electric fields inherent
with plasma delivery, which interact with the cells and other living organisms. In many cases, it has
been reported that plasma-induced apoptosis in cancer cells had no adverse effect on the normal
cells when administered at the comparable dosage provided to cancer cells [11,44,45]. The absorption
cross-section of ROS in the UV spectral range (10–400 nm) is relatively small [46], and the species lines
between 300 and 350 are still not clearly determined. Radicals and electrons generated during plasma
formation can be either short-lived or long-lived. These radicals or electrons reach a solution and
form many complex reactions, which result in the formation of other short- and long-lived radicals
or species. Short-lived radicals or species include superoxide (O2−), nitrite (NO), atomic oxygen (O),
ozone (O3), hydroxyl radical (•OH), singlet delta oxygen (SOD, O2 (1∆g)), and peroxynitrite (ONOO−),
etc. [47,48]. Long-lived species include hydrogen peroxide (H2O2) and nitrite (NO2−) [48].
In the case of indirect treatment µCAP (treatment of DI water and transfer to cells in a culture
medium), one can argue that the primary effects are associated with long-lived species (H2O2 and
NO2−). RNS are known to induce cell death via DNA damage, while ROS can induce cell death
by apoptosis and necrosis [49,50]. When He is used as a carrier gas, the concentration of H2O2 and
NO2− in DI water rises with time (Figures 3 and 5). Analyzing cell viability, one can see that He
µCAP has a strong effect on glioblastoma (U87MG) cancer cells. The µCAP-generated H2O2 and
NO2− concentration increase with treatment time, in line with the linear increase in cancer cell killing
efficiency. However, there might be additional antitumor pathways related to H2O2 and NO2−. For
example, H2O2 and NO2− are believed to generate peroxynitrite (H2O2 + 2NO2− → 2HONOO−)
which is known to be toxic to cells [51]. HONOO− is stable at basic pH (DI water < 6) or otherwise
it immediately decomposes into NO3−. However, HONOO− may be difficult to generate in media
because media is buffered and only slightly basic (pH > 7) [52]. On the other hand, aquaporins (AQPs)
play a critical role in facilitating the passive diffusion of H2O2, especially AQP8 [45,53–55]. Not all
AQPs can transport H2O2, and AQPs show various transportation degrees of H2O2 in different types
of human tumors. AQP1, 4, 8, and 9 are highly expressed in glioblastoma cell lines [45,56]. Thus,
the distinct expression pattern of AQP8 in glioblastoma might be responsible for cancer cells being
sensitive to high H2O2 concentrations.
The effect of both short- and long-lived species or radicals is plausible when considering µCAP
direct-treated glioblastoma cancer cells (in vitro, Figure 6) and tumors in the mouse brain (in vivo,
Figure 7). Of note, DMEM comprises over 30 components such as inorganic salts, amino acids and
vitamins and the effect of plasma irradiation on these compounds is still unknown. Similarly, the
effect of plasma irradiation in murine brain is also unknown. Therefore, unknown reactive species or
radicals could be generated during the irradiation of DMEM and during in vivo application. Short-
and long-lived species or radicals in DMEM and mice brain containing •OH, NO, O2−, O, O3, O2
(1∆g), ONOO−, H2O2 and NO2− are prominent components of antitumor plasma action [57]. The
relative concentration of •OH in DMEM treated by He µCAP increases with treatment time (Figure 4).
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The color change of methylene blue shows the presence of OH radicals via immediate and distinct
bleaching of methylene blue dye (qualitatively analysis) [41]. •OH-derived amino acid peroxides
can contribute to cell injury because •OH itself and protein (amino acid) peroxides are able to react
with DNA, thereby inducing various forms of damage [58,59]. When He µCAP activates DMEM, the
concentration of both H2O2 and NO2− rises with treatment time (Figures 3 and 5), and synergism
of H2O2 and NO2− mentioned above might be an important factor. CAP also produces significant
amount of ozone (O3), which is known to have strongly aggressive effect on cells [60]. Ozone has a
role in the formation of biologically active ROS and RNS in aqueous media, which may be responsible
for cell death [61,62]. Atomic oxygen (O) (including the ground state and all the excited states) is
believed to have a significant effect on cells [63,64]. Superoxide (O2−) generated by plasma can activate
mitochondrial-mediated apoptosis by changing mitochondrial membrane potential and simultaneously
up-regulates pro-apoptotic genes and down-regulates anti-apoptotic genes for activation of caspases
resulting in cell death [65]. Singlet delta oxygen O2 (1∆g) is another important ROS with the excitation
energy of 0.98 eV. Highly reactive molecule O2 (1∆g) not only produces oxidative damage in many
biological targets but is also a primary active species in the selective killing of tumor cells in the
emerging cancer therapy [66,67]. Moreover, nitrite (NO2−) and superoxide (O2−) can easily form
ONOO− once they collide [68]. ONOO− is a powerful oxidant and nitrating agent, which is known to
be highly damaging to tumor cells [69]. Overall, the above results and discussion indicate that both
direct and indirect routes of delivering CAP might be useful and should be considered in a clinical
medical application. A further understanding of the precise underlying mechanisms will allow for
determination of the “best” combination when used as a treatment strategy.
4. Materials and Methods
4.1. Experimental Device Configuration
In Figure 1a, the µCAP device consists of a two-electrode (copper) assembly with a central
powered electrode and a grounded outer electrode wrapped around the outside of a quartz tube
(10 mm). The electrodes were connected to the secondary output of a high voltage transformer.
The peak-peak voltage was about 8 kV and the frequency of the discharge was around 15 kHz.
The secondary output of the high voltage transformer was connected to the first input. The power
of the first input is around 5 watts. At the end of a quartz tube, a 70 ± 3 µm inner diameter capillary
tube (stainless steel) with a 20-mm length was attached and insulated by epoxy. The feeding gas for
this study was industrial purity helium, which was injected into the quartz tube with a 0.1 L/min gas
flow rate.
4.2. Optical Emission Spectroscopy (OES) Spectra Measurement
UV-visible-NIR, with a range of wavelength 200–850 nm, was investigated on plasma to detect
various RNS and ROS (nitrogen [N2], nitric oxide [–NO], nitrogen cation [N+2], atomic oxygen [O],
and hydroxyl radicals [–OH]). The spectrometer and detection probe were purchased from Stellar Net
Inc. (Tampa, FL, USA). The optical probe was placed at a distance of 1.0 cm in front of the plasma jet
nozzle. Data were collected with an integration time of 100 ms.
4.3. A Rayleigh Microwave Scattering System (RMS) for Electron Number Measurement
The experimental RMS system is schematically presented in Figure 2a. Two microwave horns
were used for radiation and detection of microwave signal. Microwave radiation linearly polarized
was scattered on the collinearly-oriented plasma channel and the scattered signal was then measured.
The detection of the scattered signal was accomplished using a homodyne scheme by means of an I/Q
mixer, providing in-phase (I) and quadrature (Q) outputs. For the entire range of scattered signals, the
amplifiers and mixer were operated in linear mode. The total amplitude of the scattered microwave
signal was determined by: U =
√
I2 + Q2.
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4.4. Cell Culture
Human glioblastoma cancer cells (U87MG, Perkin Elmer, Waltham, MA, USA) were cultured in
Dulbecco’s Modified Eagle Medium (DMEM, Life Technologies, Washington, WA, USA) supplemented
with 10% (v/v) fetal bovine serum (Atlantic Biologicals, Frederick, MD, USA) and 1% (v/v) penicillin
and streptomycin (Life Technologies). Cultures were maintained at 37 ◦C in a humidified incubator
containing 5% (v/v) CO2.
4.5. Determination of H2O2 Concentration
A fluorimetric hydrogen peroxide assay Kit (Sigma-Aldrich, St. Louis, MO, USA) was used for
measuring the amount of H2O2, according to the manufacturer’s protocol. Briefly, 50 µL of standard
curve, control, and experimental samples were added to 96-well flat-bottom black plates, and then
50 µL of Master Mix was added to each of well. The plates were incubated for 20 min at room
temperature protected from light and fluorescence was measured by a Synergy H1 Hybrid Multi-Mode
Microplate Reader at Ex/Em: 540/590 nm.
4.6. Determination of NO2− Concentration
RNS levels were determined by using a Griess Reagent System (Promega Corporation, Madison,
WI, USA) according to the instructions provided by the manufacturer. Briefly, 50 µL of samples and
50 µL of the provided sulfanilamide solution were added to 96-well flat-bottom plates and incubated
for 5–10 min at room temperature. Subsequently, 50 µL of the NED solution was added to each well
and incubated at room temperature for 5–10 min. The absorbance was measured at 540 nm by a
Synergy H1 Hybrid Multi-Mode Microplate Reader.
4.7. •OH Accumulation in a Methylene Blue (MB) Solution
An MB solution was prepared by dissolving MB power in DI water and DMEM. MB solutions
(100 µL per well, 0.01 g/L) in a 96-well flat-bottom black plate were treated by He µCAP for 5, 10,
30, 60, and 120 s. The gap between the outlet of µCAP and the surface of the samples was around
3 mm. As a control, two untreated MB solutions in triplicate were transferred to a 96-well flat-bottom
black plate. The color change of methylene blue shows the presence of OH radicals via immediate and
distinct bleaching of methylene blue dye (qualitatively analysis). Color change of MB solution was
measured as the absorbance at 664 nm by a Synergy H1 Hybrid Multi-Mode Microplate Reader.
4.8. Cell Viability Following µCAP Indirect Treatment In Vitro
U87 cells were plated in 96-well flat-bottom microplates at a density of 3000 cells per well in
70 µL of complete culture medium. Cells were incubated for 24 h to ensure proper cell adherence
and stability. On day 2, 30 µL of DI water was treated by He µCAP for 0, 5, 10, 30, 60, and
120 s, and was added to cells. Cells were further incubated at 37 ◦C for 24 and 48 h. The cell
viability of the glioblastoma cancer cells was measured for each incubation time point with a 3-(4,
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. A volume of 100 µL MTT
solution (Sigma-Aldrich) was added to each well followed by a 3-h incubation. The MTT solution was
discarded and 100 µL per well of MTT solvent (0.4% (v/v) HCl in anhydrous isopropanol) was added
to the wells. The absorbance of the purple solution was recorded at 570 nm with a Synergy H1 Hybrid
Multi-Mode Microplate Reader.
4.9. Cell Viability Following µCAP Direct Treatment In Vitro
U87 cells were plated in 96-well flat-bottom microplates at a density of 3000 cells per well in
100 µL of complete culture medium. Cells were incubated for 24 h to ensure proper cell adherence and
stability. On day 2, the cells were treated by He µCAP for 0, 5, 10, 30, 60, and 120 s. Cells were further
incubated at 37 ◦C for 24 and 48 h. An MTT assay was used to assess cell viability as described above.
Cancers 2017, 9, 61 12 of 16
4.10. In Vivo Application of µCAP to Target Intracranial Glioblastoma
All animal protocols were approved by the George Washington University Institutional
Animal Care and Use Committee. Eight-week-old female athymic nude mice (Charles River,
NU(NCr)-Foxn1nu) were anesthetized intraperitoneally (i.p.) (Ketamine (100 mg/kg) mixed with
Xylazine (10 mg/kg)) and placed in a stereotaxic frame. The surface of the skull was visualized with a
dissecting microscope and horizontally leveled between bregma and lambda. A small hole was drilled
at the desired location. U87MG-RedFluc cells (Perkin Elmer), containing a red-shifted firefly luciferase
that allows for in vivo monitoring of tumor growth via light emission, were resuspended in DMEM
at a concentration of 5 × 105 cell/µL and injected into the frontal lobe at the following coordinates
(relative to Bregma) using a Hamilton syringe: 2.2 mm ventral from the dorsal surface of the skull,
1.0 mm caudal, and 2.0 lateral. Then, 5 × 105 cells were injected at a depth of 2.2 mm and the syringe
was then retracted to 1.8 mm and an additional 5 × 105 cells were then administered. To allow for
delivery of µCAP, an endoscopic tube was then implanted at a depth of 2.2 mm and secured in place
with dental cement. Mice were allowed to recover for 7 days and He µCAP or vehicle control (He
alone) was then administered. In brief, mice were anesthetized with isofluorane and CAP was applied
via the implanted endoscopic tube at 5-s intervals, followed by 15 s off, for a total CAP treatment
time of 15 s. The jet was removed from the endoscopic tube to allow for venting of He. Tumor size
was estimated using in vivo bioluminescent imaging before and for up to 48 h post CAP or vehicle
treatment. For bioluminescent imaging, animals were anesthetized with isoflurane and the substrate
luciferin was administered i.p., (150 mg/kg). The mice were then transferred to the light-sealed
imaging cabinet of an IVIS Lumina K machine and positioned in a nose cone in order to maintain
anesthesia. Bioluminescent images were acquired using a charge-coupled device camera cooled to
−80 ◦C to achieve maximal sensitivity. Images were acquired at 10 min post substrate injection with
an exposure time of 20 s, medium binning, F/Stop = 1, and EM gain off.
4.11. Definition of Control
In Figures 4 and 6, there are “0 s” treatments, which represent no µCAP treatment used as control.
4.12. Statistical Analysis
Results were plotted using Origin 8 as mean ± standard deviation. Student t-test was used to
check the statistical significance (* p < 0.05, ** p < 0.01, *** p < 0.001).
5. Conclusions
In summary, the effect of a newly developed µCAP on glioblastoma both in vitro and in vivo
has been demonstrated. A variety of diagnostics tools were applied to the µCAP, including optical
emission spectroscopy, microwave scattering, and potential measurement, which supplied evidence
for reactions of plasma-generated species in media and the mouse brain. The µCAP direct treatment
has a stronger effect than the indirect treatment due to the synergetic effect of short- and long-lived
species, while a strong effect of indirect µCAP treatment on cancer cells is likely attributed to the action
of long-lived species. The µCAP is safe for mice and suppresses tumor growth in the mouse brain.
These initial observations establish µCAP as a potentially useful ablative therapy in glioblastoma.
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